Previous 10 | Next 10 |
2023-10-10 13:49:05 ET More on Erasca Seeking Alpha’s Quant Rating on Erasca Historical earnings data for Erasca Financial information for Erasca For further details see: Erasca Chairman & CEO acquires stake worth $2.03M
2023-10-10 12:19:25 ET What has been an otherwise bullish week was originally expected to become extremely volatile heading into mid-week. While things appear to be business as usual for a stock market rally could change quickly starting Wednesday, October 11th. What’s going on in th...
2023-10-10 10:00:01 ET More on Health Care Select Sector SPDR Citi turns cautious on pharmaceuticals and biotech BofA Securities: Which small cap non-earner stocks to avoid Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR For further deta...
SAN DIEGO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate i...
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate i...
Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors Initial Phase 1b combination data from SEACRAFT-1 expected in Q2-Q4 2024 Dosing of first patient in pivotal SEACRAFT-2 trial in NRAS-mutant m...
2023-08-28 06:05:45 ET Summary Two new sample Breakout Stocks for Week 35 curated by the MDA model for a 10% short-term upside along with a Dow pick. The Momentum Gauges, S&P 500 Gauges, and Weekly Gauges all continue negative after the longest positive signal since March 2021...
2023-08-14 15:22:00 ET Summary Two new Breakout Stocks for Week 33 curated by the MDA model for 10% short-term upside along with one Dow pick. Last week two of four picks gained over the 10% mark in less than a week with peak gains in EHTH +12.3% and ATEX +15.4% still near highs. ...
2023-08-11 12:40:10 ET Erasca press release ( NASDAQ: ERAS ): Q2 GAAP EPS of -$0.21 beats by $0.02 . Cash, cash equivalents, and marketable securities of $365 million as of June 30, 2023, expected to fund operations into H2 2025 For further details see: Erasc...
2023-08-11 10:14:56 ET Gainers: Eton Pharmaceuticals ( ETON ) +23% . Semler Scientific ( SMLR ) +20% . ModivCare ( MODV ) +15% . Erasca ( ERAS ) +9% . Relmada Therapeutics ( RLMD ) +8% . Losers: Cano Health ( CANO ) -...
News, Short Squeeze, Breakout and More Instantly...
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to date Favorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanoma Randomi...
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., cha...
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed und...